Introduction
After claims that the presence of oestrogen-binding components ("receptors") in human malignant breast tumours may be related to their response to endocrine therapy (Jensen et al., 1973; Maass et al., 1972 ) much work has recently been published on the quantitative determination of these substances. Though estimates of tumour affinity for oestrogen by an in-vivo tracer infusion technique may yield results which are independent of plasma oestrogen levels in-vitro methods involving incubation of tracer with tissue extracts (Korenman and Dukes, 1970) are believed to estimate free-that is, unoccupied-oestrogen binding sites because the endogenous hormone dissociates only slowly from its complex (Feherty et al., 1971) . It is therefore possible that the estimated concentrations of "receptor" and the incidence of "receptorpositive" tumours depend on plasma oestrogen levels and thus on the patient's age and menopausal status.
Some studies support this possibility (Maass et al., 1972; Feherty et al., 1971; Savlov et al., 1974; Spaeren et al., 1973 and 76 tumours studied by an in-vitro technique (Feherty et al., 1971 ).
Patients and Methods
Patients were grouped according to their age or their menopausal status; group 1 were premenopausal, group 2 were symptomatically menopausal, group 3 had been postmenopausal for a period up to and including five years, and group 4 had been postmenopausal for more than five years. All tumours were primary lesions whose malignancy was confirmed histologically.
In the in-vivo study the 105 patients were infused with tritium-labelled oestradiol at a constant rate for at least three hours before and during surgery. Under these conditions equilibrium is approached in the tissues between isotopic oestrogen and the endogenous exchangeable hormone. Tissue and plasma obtained at operation were extracted to yield the free steroid moiety, and the concentration of radioactive steroid in the tissue was a measure of the concentration of endogenous hormone present . Oestrogen uptake was expressed as the ratio of radioactivity per gram of tissue (T) to that per millilitre of plasma (P).
For the in-vitro study the method of Feherty et al., (1971) was used. Tissue extracts were incubated with varying amounts of tritium-labelled oestradiol which attaches to binding sites if present. Subsequent incubation with dextran-coated charcoal removed free oestradiol and dissociated the steroid from lowaffinity sites leaving that bound to high-affinity "receptor" in solution. Determination of bound radioactivity at different concentrations of tracer yielded estimates of binding sites. fig. 2 . No significant differences were found between the groups, but when groups 1, 2, and 3
were combined the mean T :P (2.1) was just significantly different from that (3.2) for group 4 (P <0 05).
In the in-vitro study 58 out of 76 tumours (76%) were found to bind oestradiol-that is, to be "positive." The incidence of "positive" tumours in relation to age is shown in table I. The younger patients showed a high incidence while those in the fifth and sixth decades showed lower incidences. Greater proportions of "positive" tumours were again found at higher ages. These data are shown in relation to menopausal status fig. 4 . There were few results in groups 1, 2, and 3, but when the mean for groups 1, 2, and 3 was compared to that for group 4 the difference was highly significant (P <0001).
The results of a study in which 23 tumours were examined by both the in-vivo and the in-vitro techniques are shown in fig. 5 . The small amount of tritium present in the tissues as a result of the infusions was negligible in relation to the concentrations added in the in-vitro assay. Though there was a significant correlation (r=081; P <0001) the figures were widely scattered at all levels. 
Discussion
While in-vitro estimates of concentrations of oestrogen-binding components in breast-tumour tissues seem to be related to a patients' age and menopausal status no convincing correlation could be shown for results of uptake studies in vivo. A possible explanation is that in-vivo, where equilibrium is approached between the tracer and endogenous hormone in blood and tissue, results are independent of the plasma level of endogenous oestrogen, while in-vitro much of the endogenous hormone remains attached to binding sites and the proportion of unoccupied sites present is related to plasma oestrogen concentration. In addition, it is likely that in the in-vivo studies some tracer steroid binds to low-affinity binding components, now known to be present in tumour tissue (Jensen et al., 1973) , while such binding is largely dissociated in the in-vitro method (Feherty et al., 1971) . For tumours with a high capacity of lowaffinity components estimates of high-affinity "receptors" are unreliable by both techniques. Furthermore, the in-vivo method probably yields results which are less precise than those by the in-vitro technique. In spite of these differences a correlation has been found between the in-vivo and in-vitro results and it is likely that when "receptor" concentrations are high both methods are capable of indicating this clearly. At lower "receptor" concentrations, however, results by the in-vitro method may become more dependent on endogenous levels of oestrogen.
Other work has indicated a relationship between results of in-vitro analyses and patients' ages and menopausal status. Of the series reported by Savlov et al. (1974) the highest values were found in women over the age of 55. Spaeren et al. (1973) It has been reported (Jensen et al., 1973; Maass et al., 1972) that there is much prognostic significance in the presence of oestrogen receptors in breast-tumour tissue and that there is little likelihood of a patient responding to endocrine therapy if oestrogen receptors cannot be detected. Our own data from an in-vivo study (Braunsberg et al., 1973) and from our in-vitro determinations suggest that though this conclusion is true in most cases there are occasional exceptions for which no obvious explanation exists. Similar findings have also been reported at a recent meeting (McGuire et al., in press) by several other groups using in-vitro methods. It would therefore seem that a patients' response to treatment cannot yet be predicted with complete confidence from these biochemical studies. Though this may be a consequence of technical problems in the estimation of receptors other factors-such as menopausal status and stage of the disease-may play an important part in some patients.
